Prospective study on anti-islet autoantibody and glucose tolerance in chronic hepatitis C patients treated with interferon.

Not Applicable

• Conditions: Chronic hepatitis C

• Registration Number: JPRN-UMIN000013585
• Lead Sponsor: Department of Gastroenterology and Hepatology, Okayama University Hospital

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2014-04-01
• Last Update Posted: 17 October 2023
• Study Completion: 2023-12-31

Recruitment & Eligibility

• Status: Complete: follow-up continuing
• Sex: All
• Target Recruitment: 78

Inclusion Criteria

Not provided

Exclusion Criteria

Patients with the followings: other viral infections such as infection with the hepatitis B virus or human immunodeficiency virus; any other cause of liver disease, e.g., autoimmune hepatitis, primary biliary cirrhosis, drug-induced liver disease, and excessive daily intake of alcohol (>40 g per day over the period of more than 5 years); relevant disorders, including decompensated liver disease, cirrhosis, hepatocellular carcinoma, and other malignant neoplastic diseases; concomitant use of immunosuppressive or herbal medications (e.g. Sho-saiko-to); current use of intravenous drugs; poorly controlled diabetes mellitus, hypertension, cardiovascular disease, chronic renal failure, or creatinine clearance values <50 mL/min.

Study & Design

• Study Type: Observational
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Positive rate of anti-islet autoantibodies.

Secondary Outcome Measures

Name	Time	Method
Changes in glucose tolerance.